Remove 2019 Remove Blogging Remove Pricing Remove San Diego
article thumbnail

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Xconomy

Gossamer Bio, the San Diego-based biotech founded by former Receptos executives, has raised $276 million in its initial public offering, a total that puts it in a rare class among biotechs that have gone public in recent years. The amount raised surpassed expectations. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

article thumbnail

SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future

Xconomy

biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. After years of boom times, the U.S. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way.

Report 83
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup

Xconomy

The larger company agreed to pay $12 per share for Pfenex (NYSE American: PFNX )—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: LGND ) generates revenue from licensing deals and royalties paid by pharmaceutical companies that use technologies it develops or acquires for their own drug research.

article thumbnail

Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

Xconomy

It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

Pricing 73
article thumbnail

SPECIAL REPORT: 2019 Blockchain Outlook — Reality Check

Xconomy

After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.

Report 98
article thumbnail

Two Days, Five Biotech IPOs, and $359M Raised for Clinical Trials

Xconomy

Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. To date in 2019, 23 healthcare-related companies have gone public, the most of any sector.

Pricing 110
article thumbnail

Led by Tech, Healthcare Debuts, IPOs in 2019 Show Positive Returns

Xconomy

Even as Uber, Lyft, and other high-profile initial public offerings underperformed out of the gate, the average share price of companies that have gone public in the US this year is up by almost 33 percent. percent compared to their offer price at IPO. On average, those companies’ shares are up 32.6

Startup 69